![](/img/cover-not-exists.png)
Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population
B. Fagerberg, S. Edwards, T. Halmos, J. Lopatynski, H. Schuster, S. Stender, G. Stoa-Birketvedt, S. Tonstad, S Halldórsdóttir, I. Gause-NilssonVolume:
48
Language:
english
Pages:
10
DOI:
10.1007/s00125-005-1846-8
Date:
September, 2005
File:
PDF, 241 KB
english, 2005